Page 167 of 439: studies 1,661 to 1,670 of 4,389, newest first. Back to the psilocybin overview
Frontiers in Psychiatry July 3, 2018 Joseph M Barnby, Mitul A. Mehta 18 citations
OPINION article Front. Psychiatry, 03 July 2018Sec. Psychopharmacology Volume 9 - 2018 | https://doi.org/10.3389/fpsyt.2018.00293
ACS Chemical Neuroscience June 29, 2018 Haden A. Geiger, Madeline G. Wurst, R. Nathan Daniels 139 citations
Psilocybin is found in a family of mushrooms commonly known as "magic mushrooms" that have been used throughout history to induce hallucinations. In the late 1950s Albert Hofmann, of Sandoz Laboratories, identified and synthesized the psychoactive compounds psilocybin and psilocin which are found in psilocybe mushrooms. Psilocybin was marketed by Sandoz as Indocybin for basic...
Journal of Psychopharmacology June 27, 2018 Christopher R. Nicholas, Kelsey M. Henriquez, Michele Gassman et al. 85 citations
Aim: The aim of the current study was to investigate the relationship between escalating higher doses of psilocybin and the potential psilocybin occasioned positive subjective effects. Methods: Healthy participants ( n=12) were given three escalating doses of oral psilocybin (0.3 mg/kg; 0.45 mg/kg; 0.6 mg/kg) or (18.8–36.6 mg; 27.1–54.0 mg; 36.3–59.2 mg) a minimum of four weeks apart in a...
Acta Psychiatrica Scandinavica June 19, 2018 David Erritzøe, Leor Roseman, Matthew M. Nour et al. 268 citations
Objective To explore whether psilocybin with psychological support modulates personality parameters in patients suffering from treatment‐resistant depression (TRD). Method Twenty patients with moderate or severe, unipolar, TRD received oral psilocybin (10 and 25 mg, one week apart) in a supportive setting. Personality was assessed at baseline and at 3‐month follow‐up using the Revised NEO...
Neuropharmacology June 5, 2018 Matthew W. Johnson, Roland R. Griffiths, Peter S. Hendricks et al. 348 citations
This review assesses the abuse potential of medically-administered psilocybin, following the structure of the 8 factors of the US Controlled Substances Act (CSA). Research suggests the potential safety and efficacy of psilocybin in treating cancer-related psychiatric distress and substance use disorders, setting the occasion for this review. A more extensive assessment of abuse potential...
Chemistry - A European Journal May 11, 2018 Felix Blei, Florian Baldeweg, Janis Fricke et al. 51 citations
Abstract Psilocybin (4‐phosphoryloxy‐ N , N ‐dimethyltryptamine) is the main alkaloid of the fungal genus Psilocybe , the so‐called “magic mushrooms.” The pharmaceutical interest in this psychotropic natural product as a future medication to treat depression and anxiety is strongly re‐emerging. Here, we present an enhanced enzymatic route of psilocybin production by adding TrpB, the tryptophan...
Pain Management May 1, 2018 Andy Whelan, Mark I Johnson 51 citations
Recently, there has been interest in lysergic acid diethylamide (LSD) and psilocybin for depression, anxiety and fear of death in terminal illness. The aim of this review is to discuss the potential use of LSD and psilocybin for patients with persistent pain. LSD and psilocybin are 5-hydroxytryptamine receptor agonists and may interact with nociceptive and antinociceptive processing. Tentative...
European Neuropsychopharmacology April 25, 2018 O. Grimm, Rainer Kraehenmann, Katrin H. Preller et al. 94 citations
Recent studies suggest that the antidepressant effects of the psychedelic 5-HT2A receptor agonist psilocybin are mediated through its modulatory properties on prefrontal and limbic brain regions including the amygdala. To further investigate the effects of psilocybin on emotion processing networks, we studied for the first-time psilocybin's acute effects on amygdala seed-to-voxel connectivity...
Frontiers in Pharmacology April 3, 2018 Tara C. Malone, Sarah E. Mennenga, Jeffrey Guss et al. 128 citations
A growing body of evidence shows that existential and spiritual well-being in cancer patients is associated with better medical outcomes, improved quality of life, and serves as a buffer against depression, hopelessness, and desire for hastened death. Historical and recent research suggests a role for psilocybin-assisted psychotherapy in treating cancer-related anxiety and depression. A...
Journal of Affective Disorders April 1, 2018 Facundo Carrillo, Mariano Sigman, Diego Fernández Slezak et al. 57 citations
Background: Natural speech analytics has seen some improvements over recent years, and this has opened a window for objective and quantitative diagnosis in psychiatry. Here, we used a machine learning algorithm applied to natural speech to ask whether language properties measured before psilocybin for treatment-resistant can predict for which patients it will be effective and for which it will...